2021
Role of vitamins and minerals as immunity boosters in COVID-19
Kumar P, Kumar M, Bedi O, Gupta M, Kumar S, Jaiswal G, Rahi V, Yedke NG, Bijalwan A, Sharma S, Jamwal S. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology 2021, 29: 1001-1016. PMID: 34110533, PMCID: PMC8190991, DOI: 10.1007/s10787-021-00826-7.Peer-Reviewed Original ResearchConceptsRole of vitaminsCOVID-19SARS-CoV-2 COVID-19Immune systemSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Multiple inflammatory responsesSyndrome coronavirus 2Chronic infectious diseaseCOVID-19 infectionBalanced nutritional dietUsage of vitaminCoronavirus 2Inflammatory responsePlasma concentrationsImmune stateMortality rateVitamin AImmunity boosterMeaningful therapiesNarrative reviewSystem strengtheningCoronavirus diseaseNeuroprotection through G-CSF: recent advances and future viewpoints
Rahi V, Jamwal S, Kumar P. Neuroprotection through G-CSF: recent advances and future viewpoints. Pharmacological Reports 2021, 73: 372-385. PMID: 33389706, DOI: 10.1007/s43440-020-00201-3.Peer-Reviewed Original ResearchConceptsGranulocyte-colony stimulating factorNeutrophilic granulocyte lineageNumerous cell typesJAK/STATG-CSF receptorPI3K/AktInhibition of apoptosisTransduction pathwaysHaemopoietic stem cellsMAP kinaseNeuronal differentiationHematopoietic stemCell typesGranulocyte lineageNeurological disordersStem cellsProgenitor cellsRecent pre-clinical studiesHematopoietic growth factorsAttractive targetChemotherapy-associated neutropeniaStimulation of neurogenesisObserved neuroprotective effectsDifferentiationPre-clinical studies
2020
Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder. Molecular Biology Reports 2020, 47: 9895-9912. PMID: 33263931, DOI: 10.1007/s11033-020-06033-x.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDocosahexaenoic acidAlzheimer's diseaseArachidonic acidLipid mediatorsAnti-inflammatory actionAppropriate therapeutic optionPro-inflammatory eicosanoidsProduction of eicosanoidsResolution of inflammationRole of AACOX-2 enzymeLOX pathwayNeuroinflammatory responseNeuroinflammatory eventsTherapeutic optionsAD patientsCytokine secretionEpidemiological studiesLeukocyte traffickingNF-κBEicosanoid productionBrain disordersNeurological disordersCyclooxygenasePPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising targetGene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHDAn updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sciences 2020, 257: 118105. PMID: 32687917, PMCID: PMC7366108, DOI: 10.1016/j.lfs.2020.118105.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsSARS-CoV-2Secondary complicationsPathogenic SARS-CoV-2Hospitalized COVID-19 patientsRecovered COVID-19 patientsCOVID-19Brief clinical updatesNew SARS-CoV-2 virusCOVID-19 pathogenesisACE-2Broad-spectrum antiviral drugsCOVID-19 infectionCoronavirus disease 2019Vaccines/drugsSARS-CoV-2 virusHepatic complicationsViral burdenConvalescent plasmaClinical updateAngiotensin IIImmune damageEpidemiological featuresClinical trialsDisease 2019
2019
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Jamwal S, Kumar P. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review. Current Neuropharmacology 2019, 17: 165-175. PMID: 29512464, PMCID: PMC6343208, DOI: 10.2174/1570159x16666180302115032.Peer-Reviewed Original ResearchConceptsParkinson's diseaseHuntington's diseaseStriatal neurotransmittersNeuronal deathNeurotransmitter levelsAltered neurotransmitters levelBasal ganglia regionsExcitotoxic neuronal deathNeurotransmitter alterationsBrain dopaminePathophysiological basisBasal gangliaGanglia regionsMovement disordersPreclinical studiesReceptor densitySpecific drugsCoordinated body movementsDiseaseNeurotransmittersAltered levelsOxidative stressExact mechanismMitochondrial dysfunctionImportant neurotransmitterTherapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors.
Jamwal S, Mittal A, Kumar P, Alhayani DM, Al-Aboudi A. Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors. Current Pharmaceutical Design 2019, 25: 2892-2905. PMID: 31333104, DOI: 10.2174/1381612825666190716112319.Peer-Reviewed Original ResearchConceptsCentral nervous systemNervous systemFast excitatory postsynaptic currentsCerebral blood flowExcitatory postsynaptic currentsPeripheral nervous systemAntagonists of A1Pharmacology of adenosineA3 adenosine receptorAutonomic gangliaPostsynaptic currentsReceptor agonistMetabolic dysfunctionBlood flowNeuronal activityOcular diseasesSynaptic terminalsTherapeutic strategiesAdenosine receptorsTherapeutic potentialChemical transmissionATP actsExtracellular concentrationReceptors vizNerve signals
2017
Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review
Koshal P, Jamwal S, Kumar P. Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review. Neuropharmacology 2017, 136: 271-279. PMID: 29129776, DOI: 10.1016/j.neuropharm.2017.11.015.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Neurotransmitter systemsAltered neurotransmittersProtective roleNeurological disordersNeurotransmitter signalingProgression of seizuresGABAergic neurotransmitter systemAnti-epileptic drugsManagement of epilepsyGLP-1 analoguesGLP-1 receptorTreatment of epilepsyFuture drug therapiesOnly symptomatic reliefBasic pathogenic mechanismsPrevalent neurological disordersPreproglucagon neuronsSymptomatic reliefGlutamatergic systemPathophysiological mechanismsDrug therapyRisk factorsMetabolic impairmentPeptide-1
2015
Antidepressants for neuroprotection in Huntington's disease: A review
Jamwal S, Kumar P. Antidepressants for neuroprotection in Huntington's disease: A review. European Journal Of Pharmacology 2015, 769: 33-42. PMID: 26511378, DOI: 10.1016/j.ejphar.2015.10.033.Peer-Reviewed Original ResearchConceptsHuntingtin proteinHuntington's diseaseMAPK/ERK signalingBrain-derived neurotrophic factor (BDNF) productionBDNF/TrkB pathwayProgression of HDDifferent neuroprotective mechanismsPrincipal neuropathological hallmarksUse of antidepressantsNeurotrophic factor productionCortical projection neuronsMutant huntingtin proteinCellular functionsPolyglutamine stretchMolecular mechanismsNH2 terminusERK signalingTrkB pathwayPreclinical evidenceNeuroprotective effectsNeuroprotective mechanismsCommon symptomsProjection neuronsAvailable treatmentsDisease progression
2014
Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders
Rana A, Goyal N, Ahlawat A, Jamwal S, Reddy B, Sharma S. Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders. Perfusion 2014, 30: 94-105. PMID: 24947460, DOI: 10.1177/0267659114536760.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideIschemic preconditioningDiabetes mellitusMitochondrial permeability transition poreMito-KATP channelChronic diabetes mellitusGene-related peptideCardio-protective roleIschemia/reperfusionSub-lethal ischemiaGlycogen synthase kinase-3βSynthase kinase-3βCardioprotective effectsMyocardial damageMyocardial infarctionBlood supplyPart of heartMetabolic disordersInvolvement of PTENBeneficial effectsPTEN inhibitorKinase-3βPathological statesMellitusHyperlipidemia